BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22197189)

  • 1. Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples.
    Martínez SB; Palomares JC; Artura A; Parra M; Cabezas JL; Romo JM; Martín-Mazuelos E
    J Virol Methods; 2012 Mar; 180(1-2):7-10. PubMed ID: 22197189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.
    Yu S; Kwon MJ; Lee EH; Park H; Woo HY
    J Med Virol; 2015 Sep; 87(9):1587-93. PubMed ID: 25914215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology.
    Pesic A; Krings A; Hempel M; Preyer R; Chatzistamatiou K; Agorastos T; Kaufmann AM
    Virol J; 2019 Jul; 16(1):92. PubMed ID: 31337408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Roche Cobas(®) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia.
    Phillips S; Garland SM; Tan JH; Quinn MA; Tabrizi SN
    J Clin Virol; 2015 Jan; 62():63-5. PubMed ID: 25542473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders.
    van Ham MA; Bakkers JM; Harbers GK; Quint WG; Massuger LF; Melchers WJ
    J Clin Microbiol; 2005 Jun; 43(6):2662-7. PubMed ID: 15956381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enhanced molecular techniques for the diagnosis of human papillomavirus infections].
    Ursu RG; Onofriescu M; Nemescu D; Iancu LS
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1205-10. PubMed ID: 20191900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens.
    Kaliterna V; Židovec Lepej S; Vince A
    J Med Microbiol; 2009 Dec; 58(Pt 12):1662-1663. PubMed ID: 19661205
    [No Abstract]   [Full Text] [Related]  

  • 8. Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples.
    Bartholomew DA; Luff RD; Quigley NB; Curtis M; Olson MC
    J Clin Virol; 2011 May; 51(1):38-43. PubMed ID: 21376660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
    Sandri MT; Lentati P; Benini E; Dell'Orto P; Zorzino L; Carozzi FM; Maisonneuve P; Passerini R; Salvatici M; Casadio C; Boveri S; Sideri M
    J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland.
    Anderson LA; O'Rorke MA; Wilson R; Jamison J; Gavin AT;
    J Med Virol; 2016 Jul; 88(7):1262-70. PubMed ID: 26680281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting.
    Venturoli S; Leo E; Nocera M; Barbieri D; Cricca M; Costa S; Santini D; Zerbini M
    J Clin Virol; 2012 Feb; 53(2):121-4. PubMed ID: 22115872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
    Chung HS; Hahm C; Lee M
    J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test.
    Yang HP; Walmer DK; Merisier D; Gage JC; Bell L; Rangwala S; Shrestha N; Kobayashi L; Eder PS; Castle PE
    J Virol Methods; 2011 Sep; 176(1-2):112-4. PubMed ID: 21640138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.
    Halfon P; Trepo E; Antoniotti G; Bernot C; Cart-Lamy P; Khiri H; Thibaud D; Marron J; Martineau A; Pénaranda G; Benmoura D; Blanc B;
    J Clin Microbiol; 2007 Feb; 45(2):313-6. PubMed ID: 17122007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping.
    Castle PE; Sadorra M; Lau T; Aldrich C; Garcia FA; Kornegay J
    J Clin Microbiol; 2009 Oct; 47(10):3344-7. PubMed ID: 19675214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type-specific human papillomavirus prevalence in cervical intraepithelial neoplasia and cancer in Iran.
    Heydari N; Oskouee MA; Vaezi T; Shoja Z; Esmaeili HA; Hamkar R; Shahmahmoodi S; Jalilvand S
    J Med Virol; 2018 Jan; 90(1):172-176. PubMed ID: 28786495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation and budget impact analysis of cervical cancer screening using cobas 4800 HPV screening technology in the public sector of South Africa.
    Dreyer G; Maske C; Stander M
    PLoS One; 2019; 14(9):e0221495. PubMed ID: 31509545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of high-risk human papillomavirus by cobas 4800 HPV test in urban Peru.
    Iwasaki R; Galvez-Philpott F; Arias-Stella J; Arias-Stella J
    Braz J Infect Dis; 2014; 18(5):469-72. PubMed ID: 24835620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.